Industry News Pfizer BioSpace
Bourla: Chinese biotechs will be Pfizer's main rivals by 2030, and AI is the answer
- At the Jefferies healthcare conference in London, Pfizer CEO Albert Bourla said that by 2030 his main competitors will be Chinese companies, working at 3-4x the speed and half the cost.
- He called AI the biggest lever for catching up, across the whole business including sales and marketing.
- China's five-year plan targets discovering a third of global blockbuster drugs by 2030.
Bourla's own deals undercut the rhetoric: Pfizer's recent licensing with Innovent, Sciwind and Starna means it is buying the Chinese speed it says it fears. The AI-savings claim is the unproven part, since drug R&D cost is dominated by clinical trials that AI doesn't yet shorten. Expect more big-pharma in-licensing from China, and a push to show internal cost cuts, as the realistic response.
Source: BioSpace ↗ In China's shadow, Pfizer CEO calls for AI savings to bolster Big Pharma